Norma Beauchamp

Ms. Beauchamp is a corporate director with over 30 years of healthcare experience in corporate and non-profit organizations, including executive positions at Bayer Healthcare (Canada and Global) and Sanofi Canada. Most recently, she served as the President and CEO of Cystic Fibrosis Canada (2014 to 2017). Throughout her career, she has been a patient advocate, working with patients and healthcare organizations to enhance access to care.

Ms. Beauchamp currently serves on the respective boards of Aurora Cannabis Inc. (TSX: ACB), as Chair of its Nominating and Corporate Governance Committee and a member of its Human Resources and Compensation Committee, Dialogue Health Technologies Inc. (TSX: CARE), a leading Canadian telehealth service, and HLS Therapeutics Inc. (TSX: HLS). Formerly, Ms. Beauchamp served on the respective boards of Acerus Pharmaceuticals Corporation (TSX: ASP), as Chair of its Corporate Governance and Nominating Committee and a member of its Audit Committee; Quest PharmaTech Inc. (TSXV: QPT); and prior to its acquisition by Aurora, MedReleaf as Chair of its Corporate Governance and Compensation Committee and a member of its Audit Committee.